Research Focus
We are currently focused on several disease areas, including but not limited to immuno-oncology (e.g., liver cancer, lung cancer, and gastrointestinal tumors), fibrosis (e.g., liver fibrosis, pulmonary fibrosis, and renal fibrosis), autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, and systemic lupus erythematosus), and aging-associated changes of the immune system.
Overview
Drug Development
6 warheads and 3 pipeline projects have finished HIT.
| Project Code | Indication | Drug Design | HIT | Lead Optimization | PCC | |
|---|---|---|---|---|---|---|
| Warhead | CI-01 | Solid Cancer |
|
|||
| CI-02 | Solid Cancer |
|
||||
| CI-03 | Solid Cancer |
|
||||
| CI-05 | Solid Cancer |
|
||||
| CI-08 | Autoimmune Diseases |
|
||||
| CI-09 | Autoimmune Diseases |
|
||||
| Pipeline | BP-201 | Autoimmune Diseases |
|
|||
| BP-101 | Solid Cancer |
|
||||
| BP-102 | Solid Cancer |
|
||||
Target Discovery
cover 10+ oncology or autoimmune diseases, 8 candidate targets entered in-vitro validation stage.
| Proj Class | Data Preparation | Target Recommendation | Dry-lab Evaluation | In-vitro Validation | In-vivo Validation |
|---|---|---|---|---|---|
| Tumor-specific targets mining |
|
||||
| Autoimmune diseases targets mining |
|
||||
| Fibrosis diseases targets mining |
|
||||
| Immune cells targets mining |
|
||||
Collaborations
10 +diseases with unmet clinical needs 20 top tier academic hospitals 30 top tier PIs 30 projects
Representative Projects
Esophageal Cancer
Zhihua LIU, M.D.
- Top-tier cancer hospital with annual outpatient volume >730k, inpatient volume >53k and surgery volume >18k
- Director of State Key Laboratory of Molecular Oncology
- KOL in esophageal cancer
Gastric Cancer
Jiafu JI, M.D.
- Top-tier cancer hospital with annual outpatient volume >750k, inpatient volume >96k and surgery volume >17k
- Director of Peking University Cancer Research Center
- KOL in gastric cancer
Inflammatory Bowel Disease
Huji XU, M.D.
- Top-tier hospital with outstanding strength in rheumatic immunology
- Professor of Tsinghua University School of Medicine
- Clinical researcher of Center for Life Sciences jointly established by Tsinghua and Peking University
Rheumatoid Arthritis
Zhanguo LI, M.D.
- Top-tier hospital with outstanding strength in rheumatic immunology
- Director of Clinical Immunity Center and Department of Rheumatology and Immunology in Peking University
